BMC Pulmonary Medicine (Oct 2021)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis

  • Koichi Miyashita,
  • Masato Karayama,
  • Yusuke Inoue,
  • Hironao Hozumi,
  • Yuzo Suzuki,
  • Kazuki Furuhashi,
  • Tomoyuki Fujisawa,
  • Noriyuki Enomoto,
  • Yutaro Nakamura,
  • Masato Kono,
  • Takashi Matsui,
  • Mitsuru Niwa,
  • Keigo Koda,
  • Mikio Toyoshima,
  • Sayomi Matsushima,
  • Shun Matsuura,
  • Kazuhiro Asada,
  • Masato Fujii,
  • Hideki Kusagaya,
  • Hiroyuki Matsuda,
  • Naoki Inui,
  • Takafumi Suda

DOI
https://doi.org/10.1186/s12890-021-01681-6
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Clinical efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC) with uncommon histology (uNSCLC) is unknown. Methods Patients with NSCLC treated with ICI monotherapy between January 2014 and December 2018 in 10 Japanese hospitals were retrospectively evaluated. The patients were divided into: (1) NSCLC with common histology (cNSCLC), defined as adenocarcinoma and squamous cell carcinoma; and (2) uNSCLC, defined as incompatibility with morphological and immunohistochemical criteria for adenocarcinoma or squamous cell carcinoma. Propensity score matching was performed to balance the two groups. Results Among a total of 175 patients included, 44 with uNSCLC (10 pleomorphic carcinomas, 9 large cell neuroendocrine carcinomas, 2 large cell carcinomas, and 23 not otherwise specified) and 44 with matched cNSCLC (32 adenocarcinomas and 12 squamous cell carcinomas) were selected for analyses. Median progression-free survival (PFS) (4.4 months, 95% confidence interval [CI] 1.8–7.7 months) and overall survival (OS) (11.4 months, 95% CI 7.4–27.4 months) in the uNSCLC patients were not significantly different from those in matched cNSCLC patients (5.4 months, 95% CI 3.1–7.6 months, p = 0.761; and 14.1 months, 95% CI 10.6–29.6 months, p = 0.381). In multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0–1 and programmed death ligand-1 (PD-L1) expression were predictive for PFS and OS in uNSCLC. Conclusions ICIs had similar clinical efficacy for treatment of uNSCLC and cNSCLC. Good ECOG-PS and PD-L1 expression were predictive for efficacy of ICIs in uNSCLC.

Keywords